Article Text

Download PDFPDF
Randomised controlled trial
Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women
  1. Sarah Fidler1,
  2. Peter Bock2
  1. 1Department of Medicine, Imperial College London, London, UK
  2. 2Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa
  1. Correspondence to : Dr Sarah Fidler
    Department of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ, UK; s.fidler{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Antiretroviral therapy (ART) has dramatically changed both mortality and morbidity associated with HIV infection, but treatment is lifelong and costly. The greatest disease burden, affecting 23 million people, is in Sub Saharan Africa where ART coverage for those in need is estimated at below 60%.1 The continued high rate of new infections demands urgent intervention, and, in the absence of an effective prophylactic vaccine, studies using ART to prevent HIV acquisition among uninfected individuals have been undertaken.


Baeten and colleagues report the results of a randomised trial among 4747 HIV-1–serodiscordant heterosexual couples from Kenya and Uganda comparing prophylactic single agent tenofovir (TDF), with tenofovir–emtricitabine (TDF-FTC) against placebo for pre-exposure prophylaxis …

View Full Text


  • Competing interests None.